OneVentures Welcome Image

OneVentures is a venture capital firm headquartered in Sydney, Australia that provides human and investment capital into high growth companies with a particular focus on transformative technologies.

The firm is particularly focused on opportunities originating in Australia which are poised to expand into the established and emerging global markets.

All of our Partners have founded, built and exited high-growth businesses.

Our goal is to be the leading Australian venture capital company.

Proudly supporting

Heads Over Heels
Investor Portal Log In

Connect With Us

About OneVentures

OneVentures invests in technology companies that serve or disrupt large high growth global markets. The firm has $170M in funds under management recently launching its new Innovation and Growth Fund II which is focused on growth and expansion stage technology companies.

OneVentures is managed by a team of Partners with a skill-set and track record ideally suited to collaboration with entrepreneurial management teams to foster growth and create value: a unique blend of highly successful entrepreneurs, technology business founders and corporate executives with a strong scientific pedigree, extensive off-shore experience and networks.

The OneVentures team is committed to deliver investor returns by applying this expertise to select portfolio companies with significant potential then accelerating their performance.


OneVentures Management Pty Ltd is a designate under OneVentures Nominees Pty Ltd's AFSL (Licence No: 462825) issued by the Australian Securities and Investments Commissions, authorising the Manager to provide such financial services as the Manager provides during the course of its duties as manager of the Fund.

The OneVentures Team

All Partners have many years of C-level, board and investment experience. Coupled with this is a track record of identifying investment opportunities in global markets with strong international business backgrounds and networks. The OneVentures Investment team has 7 technology related higher degrees.

Dr Michelle Deaker

Dr Michelle Deaker
Managing Partner

Dr Paul Kelly

Dr Paul Kelly
Managing Partner 

Anne-Marie Birkill

Anne-Marie Birkill
Managing Partner 

Graeme Wald

Graeme Wald

Dr Amir Zalcenstein

Dr Amir Zalcenstein
Investment Manager, Healthcare

James McGrath

James McGrath
Investment Analyst

Helen Liu

Helen Liu
Chief Financial Officer

Jelly Jakob

Jelly Jakob

Jen Ball

Jen Ball
Office Manager

Board of Directors

Walter Lewin

Walter Lewin
OneVentures Board of Directors

Simon Moore

Simon Moore
OneVentures Board of Directors

Roger Massy-Greene

Roger Massy-Greene
OneVentures Board of Directors


Innovation Fund (Fund I)

The OneVentures Innovation Fund is a $40M venture capital fund formed as an early stage venture capital Limited Partnership. This Fund was launched in 2010 with the Commonwealth Government committing $20M from its IIF programme and this funding matched by high net-worth wholesale investors.

Innovation and Growth Fund (Fund II)

The OneVentures Innovation and Growth Fund was launched in March 2014 with a target of $100M and reached that target in December 2015. Fund II is an early stage venture capital limited partnership backed entirely by Australian high net-worth wholesale investors.

Focusing on later stage (Series B and beyond) investments while still maintaining some investment activity in the earlier stage investments, Fund II is now screening investment opportunities where the experience of the OneVentures management team can be leveraged to accelerate value creation and company success.

We are currently looking for truly transformative companies to join our portfolio of innovative companies, if you think your company has what it takes, read our Application for Funding page and submit your application now.

Information for stakeholders interested in the Significant Investment Visa (SIV) Programme

Information for stakeholders interested in the Significant Investment Visa Programme can be found here.

Investment Portfolio

OneVentures Innovation Fund (Fund I)

OneVentures Innovation and Growth Fund (Fund II)

Other Investments

Latest News

  • OneVentures awarded Biomedical Translation $170M Funding

    by WE Buchan | Dec 14, 2016

    OneVentures, a venture capital Firm focused on investment in high growth, transformative technology and life sciences companies, is pleased to announce it has been selected as an investment manager for the Biomedical Translation Fund (BTF), and is launching the OneVentures Healthcare Fund III in January 2017. 

    OneVentures has been granted funding of $85 million, matching the funds it has raised with its investment partners and establishing the $170 million OneVentures Healthcare Fund III to invest in privately owned, clinical stage drug development and medical technologies. The investment mandate is in line with the guidelines of the BTF which was established by the Australian Government to provide a pool of public and private funds for investment in promising biomedical innovations with commercialisation potential.

    “OneVentures has a track record of helping commercialise the outputs of promising Australian research and innovation, by providing the funding and human capital to make this transition. The launch of this new Fund effectively doubles our capacity to invest in great Australian biomedical innovation and convert those discoveries into commercial products for the global health market,” said Dr Paul Kelly, Managing Partner of OneVentures, and head of Healthcare and LifeSciences at OneVentures.

    “We are absolutely delighted to have been selected as one of the Investment Managers for the BioMedical Translation fund. We congratulate the government on supporting investors and Australian companies alike by establishing the BTF which has been specifically designed to help companies traverse the ‘second valley of death’, providing funding for later stage developments which have achieved proof of concept, but – until now – have had few options to fund the clinical and commercial development required to advance to market.”

    The OneVentures Healthcare Fund III will be open for business in January 2017, and will be looking to make initial investments in the first half of 2017, investing $10 to $20 million in each individual company. The Fund will invest companies commercialising medical devices, drugs in clinical development or diagnostics. The Fund’s investment criteria requires that investee companies have reached clinical proof of concept, with Phase 1 or equivalent trial results; have a clear commercial, regulatory and reimbursement pathway; and clear value inflection and exit points on deal entry. The Fund has a three to five year investment horizon.



    For more information, contact:

    Paul Kelly

    Tel: +61 2 8205 7379




Full story

Contact Us

For Entrepreneurs

We are now screening companies for OneVentures Fund II which is a Series A and beyond growth fund focusing on the technology sector. To qualify for funding, your company should meet the following criteria:

  • Australian domiciled company
  • We invest in technology companies from many sectors, but we are particularly interested in companies from the following sectors: healthcare, education, mobile, media, cloud computing and data, security and privacy, machine learning, software, sensors and robotics or food security
  • If a life sciences company, your product should have a strong proof of concept and be at a minimum, in a late stage clinical trial and/or well progressed through the regulatory process
  • If from another sector, your company should be generating sustainable revenue and have a strong market validation
  • Approaching profitability with capital required to fuel growth and global expansion

If you meet the above criteria, send us a brief document (a 2-page executive summary or introductory PowerPoint is sufficient, please do not send larger documents or full information memorandums at this stage) covering at a minimum the following points to

  • Summarize in 2 sentences what your company does (this is important)
  • Identify the market, value proposition and your competitive advantage
  • Tell us about your progress to date
  • State your revenue for the last financial year and projected revenue for current financial year
  • Indicate capital required and how it will be used
  • Include 3 point bios of each executive and contact details

We will review your proposal and endeavour to revert to you within 2 weeks. 


For Investors

Investor enquiries:


General Enquiries

General enquiries:
Telephone: +61 2 8205 7379


OneVentures Pty Ltd
Level 13
179 Elizabeth Street
Sydney NSW 2000


c/- Interfinancial
Level 3, TC Beirne Building
315 Brunswick Street
Fortitude Valley QLD 4006